Pharvaris (PHVS) Bradykinin Symposium presentation summary

Mechanism of action and product overview

• Deucrictibant is an orally administered bradykinin B2 receptor antagonist developed for both prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks, including hereditary angioedema (HAE).

• The immediate-release (IR) capsule formulation enables rapid absorption and therapeutic exposure within 15–30 minutes, supporting on-demand use.

• B2R antagonism inhibits excessive bradykinin-mediated signaling, reducing endothelial permeability and halting attack progression.

RAPIDE-3 trial design and participant characteristics

• RAPIDE-3 was a double-blind, crossover, placebo-controlled phase 3 trial enrolling 134 global participants with HAE, including adolescents and adults.

• Participants self-administered deucrictibant IR or placebo for two qualifying attacks; subgroup analysis included all treated attacks.

• Demographics were balanced across North America and Europe/Rest of World, with most participants having HAE-C1INH type 1.

Efficacy outcomes

• Deucrictibant IR achieved faster onset of symptom relief than placebo in both North America (1.20 vs 6.55 hours) and Europe/Rest of World (1.28 vs >12 hours).

• Higher proportions of attacks achieved symptom relief at 4 and 12 hours with deucrictibant IR compared to placebo across all regions.

• Deucrictibant IR led to quicker reduction in attack severity and complete symptom resolution versus placebo, with consistent results across regions.

• Regional subgroup results mirrored the overall RAPIDE-3 population, confirming robust efficacy.